Investor Relations

Stock Quote - Ticker Tape


SEC Filings

  o View CEL-SCI's SEC Filings  

Corporate Presentations

  o Presentation at Biotech Showcase 2015 - January 12, 2015  


Warrant Quote



Press Releases

  o Press Releases  
  JANUARY 9, 2015
NEW STORY CEL-SCI to Present at Biotech Showcase 2015
  JANUARY 6, 2015
NEW STORY Date Set For Arbitration Trial between CEL-SCI And Clinical Research Organization Inventiv
  JANUARY 5, 2015
NEW STORY CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold Over 2013 in Its Phase III Head and Neck Cancer Trial
  DECEMBER 23, 2014
NEW STORY CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments
  DECEMBER 8, 2014
NEW STORY CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of 7 More Clinical Sites
  DECEMBER 2, 2014
NEW STORY CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period
  OCTOBER 24, 2014
NEW STORY CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million
  OCTOBER 21, 2014
NEW STORY CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering
  SEPTEMBER 29, 2014
NEW STORY CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients
  AUGUST 8, 2014
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results
  JULY 30, 2014
France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial
  JULY 15, 2014
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment

Investor Relations Contact


Gavin de Windt
Phone: +1 703-506-9460